Neurology · DepressionRegulatory Approvalregulatorynear-term

FDA Approves ANDA for Bupropion Hydrochloride by Macleods

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Macleods Pharmaceuticals4 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/27/2026, 6:04:49 AM

Assessment confidence: 68% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of Macleods' ANDA for Bupropion Hydrochloride introduces a new competitor in the depression treatment market, which could disrupt existing pricing and market share dynamics. Portfolio teams must evaluate the implications for their current products and strategies. Regulatory context from FDA (FDA AP — BUPROPION HYDROCHLORIDE (ORIG)) supports the near-term read. Assessment grounded in 23 ranked evidence items (11 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this new entrant on market dynamics and pricing strategies for existing products. The strongest clinical anchor is Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes (ClinicalTrials.gov), sponsor/company relevance (novartis). In Neurology · Depression, 7 regulatory and 3 competitive items passed relevance filtering for Macleods Pharmaceuticals.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10).

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — BUPROPION HYDROCHLORIDE (ORIG) (FDA). Entity match (bupropion hydrochloride); Regulatory pathway relevance (nda). This approval signifies a shift in the regulatory landscape for Bupropion Hydrochloride, necessitating close monitoring of compliance and market entry strategies.

Key Risks

Elevated medium regulatory exposure for Macleods Pharmaceuticals could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The entry of Macleods could lead to increased competition, potentially affecting market share and pricing for existing players in the depression treatment space.
First approval of PD‑1 inhibitors in combination with Trop-2-directed antibody-drug conjugate (ADC) in advanced TNBC, marking a potentially practice‑changing treatment option Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S.
Upside for Macleods Pharmaceuticals may improve if A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the impact of this new entrant on market dynamics and pricing strategies for existing products.

What Would Change This Assessment

This becomes more urgent if Monitor market entry timelines and any potential pricing strategies from Macleods.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — BUPROPION HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (bupropion hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BUPROPION HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (bupropion hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BUPROPION HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (bupropion hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TRAMADOL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
Treatment of Anaemia After Caesarean With Intravenous Versus Oral Iron and Postpartum Depression
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Digestive Evolution of Children With Crohn's Disease or Ulcerative Colitis Whose Anti-TNFα Treatment Was Switched to Ustekinumab Due to Paradoxical Psoriasis,
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10)
Merckhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)

Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Microneedle-based injection of Fungizone/Amphotericin B: an effective treatment for American cutaneous leishmaniasis in mice.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Observation of the therapeutic effect of flunarizine capsules combined with the Epley manoeuvre in the treatment of benign paroxysmal positional vertigo.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
From options to decisions: an innovative model for treatment sequencing in relapsing-remitting multiple sclerosis.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Associations between Age, Treatment Modality and Survival in Atypical Meningioma: Analysis of the SEER Database, 2000-2021.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Macleods Pharmaceuticals
Bupropion Hydrochloride
depression treatment market

Commercial impact

medium

The entry of Macleods could lead to increased competition, potentially affecting market share and pricing for existing players in the depression treatment space.

Regulatory impact

medium

This approval signifies a shift in the regulatory landscape for Bupropion Hydrochloride, necessitating close monitoring of compliance and market entry strategies.

What to watch

Monitor market entry timelines and any potential pricing strategies from Macleods.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.